HLB Group held the '2026 IR Day' to strengthen communication with the investment market.


HLB Group Successfully Concludes 'IR Day' with Participation of All Listed Company CEOs View original image

The event took place on April 2 at the Korea Exchange Conference Hall in Yeouido, Seoul. About 100 people, including institutional investors, asset management firms, and analysts, attended the event, which lasted for approximately 100 minutes. Notably, all 10 listed companies within the group gathered in one place, drawing significant interest from investors.


Jin Yang-gon, Chairman of HLB Group, personally presented the group's direction and growth strategy. He outlined the background behind establishing the group's core growth strategies, such as the Rhizome strategy, parallel development, and the Dot-Line-Plane strategy, and also presented the group's mid- to long-term growth direction. The event continued with both individual and integrated presentations, during which the 10 listed companies introduced their current business status and future strategies.


The chairman and the CEOs of the 10 listed companies all took the stage to engage in an open Q&A session with investors. With major research and development milestones scheduled at the group level—including the interim data presentation for the solid tumor CAR-T Phase 1 clinical trial at the American Association for Cancer Research (AACR) in April, the global Phase 3 topline results announcement for the neurotrophic keratitis (NK) treatment within the first half of the year, the U.S. Food and Drug Administration (FDA) approval decision for the new liver cancer drug in July, and the FDA approval decision for the new bile duct cancer drug in September—questions were focused on the current progress and upcoming schedules of the group's key pipelines.


There was also continued interest in new businesses that are expected to determine the future corporate value, such as HLB Panagene's AOC business strategy, HLB Genex's enzyme business expansion, and HLB Pep's development of dual-mechanism obesity treatments. Attention was also drawn to the potential for synergy through collaboration among affiliates within the group.


Chairman Jin stated, "Through this IR Day, we aimed to clearly inform the market about not only the overall business structure and growth strategy of the group but also the core businesses of each affiliate," adding, "We will continue to solidify performance and enhance corporate value based on synergy among affiliates."



Meanwhile, HLB Group is scheduled to hold an integrated shareholders' meeting for individual shareholders on April 9 at the KBIZ Hall of the Korea Federation of SMEs in Yeouido, Seoul.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing